

# Corporate Presentation



**Udaykumar K. Rakibe**  
**M.Pharm.Ph.D., MBA**

*Nashik, Maharashtra, India, 422011.*

*+91 7756848484 | [Pharmantra.expert@gmail.com](mailto:Pharmantra.expert@gmail.com) | [www.pharmantra.expert](http://www.pharmantra.expert)*

# Introduction

**PharmaMantra™** is a **Quality, Advisory, Consulting** firm founded by Udaykumar Rakibe, M.Pharm. Ph.D., MBA in August 2017. Udaykumar is highly motivated result oriented professional with three decades plus domain experience in the Pharmaceutical Quality & Operations Management in Regulatory GXP/CGMP arena. Steering organization through **complex Quality & Regulatory challenges, remediation**, transitions & building an empowered Quality Operations Team which is capable and empowered to deliver results within highly competitive products and regulatory environment.

Demonstrated track record, by leading cross functional global teams to achieve desired tactical, strategic business objectives with continued assurance of product quality and GMP compliance.

# Introduction

Enabling the process to facilitate the management at Board and Shop-Floor level to identify and help delivering strategic and transformational Quality leadership drive for imparting, Culture of Pharmaceutical Quality. Worked at global organisations across continents/ geographies to provide successful international growth initiative in Pharmaceutical, Bio-Pharmaceuticals, Herbal, Device, Healthcare, Cosmetics industry.

Mentoring, Training & handholding the site and corporate management to support and bring in the desired SOC – State of Control.

# Leadership Role - Quality Professional

## Quality


- Strategy and advise - to formulate and implement a sustainable Quality System
- Gap Assessment Audits – GxP, Pre-approval inspection (PAI) readiness
- WL/ 483, Regulatory inspectional Review, Response writing (post inspection)
- Road Map, as corrective action plan (CAP), OAI/ VAI remediation & communication
- US Products Release, Review the Data, QMS assessment, Analytical & Batch Records
- Training & Certification - GxP compliance, Data Integrity, Investigation CAPA, Root Cause,
- Due diligence of product, facilities
- PDE & OEL Certification, as per EMEA Guidance


## Advisory

- Greenfield/ Brownfield- New Project, ideation and advice for Facility, Product, Contract Test Lab
- R & D, Scale-up, Manufacturing, Quality & Compliance Strategy
- Support review the prevailing- QMS. Review, Execution, Implementation
- Instill the Culture of Quality

## Consultancy

- Quality Management – R & D, Manufacturing Operations (API, DF, Devices), CRO, CMO
- Regulatory batches, data review, help in dossier submission and site readiness
- Resource Management for SOC (state of control)
- Remediation Program, GxP Compliance Strategies





# Critical role by Udaykumar Rakibe, Ph.D. MBA As a Quality Leader

## Dabur Pharma Ltd. Manager Quality

Onco &  
Gen  
Injectable

Project &  
QMS

Herbal  
and Juice

## Gland Pharma GM- Quality Affairs & Regulatory

QMS  
General  
Injectable

MNCs  
Clientele

## Ranbaxy Labs Ltd. Asso. Director CQA

Harmonisation &  
Digitisation QMS

CMO, CRO, R&D  
Quality

# Critical role by Udaykumar Rakibe, Ph.D. MBA As a Quality Leader

**Ranbaxy Labs Ltd.**  
Director (Head India Asia Quality ops.)

Quality OPS  
07 Years

Remediation  
FDA/ MHRA

Merger  
Daichi  
Sankyo

**Intas Pharma Ltd.**  
Senior Vice President

Project SEZ

QMS  
Remediation  
FDA/ MHRA

**Wockhardt Ltd.**  
Senior Vice President

Remediation FDA/  
MHRA

Re-organisation  
Quality

# Critical role by Udaykumar Rakibe, Ph.D. MBA As a Quality Leader & Advisor

**Pharco Group Alexandria, Egypt,  
Mentor to MD & Director Quality**

Quality  
CGMP

Gap QS &  
Facilities

API(01site)  
DF(05site)

**Cenra Pharma, Taipei, Taiwan  
Riva Pharma, Canada  
Kopran Pharma, India  
Killitch Drugs, India**

**Morison Ltd., Colombo, Sri Lanka,  
Chief Quality Officer**


EU CGMP

Quality Re-  
organisation

Gap QS &  
Facilities

Commercialis  
ation Sri  
Lanka

# Span of Control, Udaykumar Rakibe, Ph.D. MBA As a Quality Leader



# Audits faced by Udaykumar Rakibe Ph.D. MBA

## As a Quality professional

Organisation	Agency	Category	Activities	Designation
Dabur Pharma	MCC, OGYI, WHO	Onco Injectables	Audit & Response	Head Quality
Gland Pharma	US-FDA, ISO 9001, MNC Clientele	Gen. Injectables	Audits, Response	Head Quality
Ranbaxy Lab	FDA/ MHRA India/ Asia/ MENA/ Africa	API Gen/ DF (all categories)	483/ WL/IA/AIP	Corp. Quality
Ranbaxy Lab	FDA/ MHRA India/ Asia Region, 8 sites	API Penem/ Gen/ DF (all categories)	483/WL/IA	Head Quality
Intas Pharma	FDA/ MHRA Matoda, SEZ	API & DF Onco/ Gen	483	Head Quality
Wockhardt Ltd.	FDA/ MHRA India/ UK/ US, 10 sites	API Gen/ Cepha/ DF/ Devices	483/WL/IA	Head Quality

### Note-

- ❑ More than two decades lead, **participated & responded - 450+ Regulatory Audits**, as Head of Regional/ Site Quality.
- ❑ Spearheaded the formulation of **Corrective Action Plan, CAP** for Remediation and Single Point Of Contact, **SPOC** for 3<sup>rd</sup> party and regulatory Audits and responses.
- ❑ Additionally performed **400plus** (between 2000-2007), **due diligence & cGMP Audits** in Global Corporate Quality role.

# Services We Provide



# Services We Provide

## **Esteemed Clientele, GMP Activities for –**

1. Abbott, 2. Aragen Pharma, 3. Anavex Inc. USA, 4. Aristo Pharma Pvt. Ltd., 5. Baxter, 6. Bliss GVS, 7. Baroque Pharma, 8. Brassica Pharma Ltd., 9. Blue Ocean Compliance, 10. Ciron Drugs, 11. ChromeCore, 12. Cenra Pharma, Hshinfong, Taiwan, 13. CIPLA- 3<sup>rd</sup> Party advisor, 14. Dicel ChiralTech-DCTI, 15. Emcure Lab. Ltd., 16. Eisai India, 17. EaishMan Consulting, 18. Hetero Labs, 19. IQGENX, 20. InnovaTech, 21. Kilitch Healthcare India Ltd., 22. Kopran, API(Mahad), 23. Kopran,DF(Khopoli), 24. Morison, Sri Lanka, 25. MJ Biopharma Ltd., 26. Megafine Chemicals Dindori, 27. Megafine Chemicals Vapi, 28. McKinsey India, 29. Metrotech Pvt Ltd DS, HYD & Vizag, 30. Optimus Pharma., 31. Pharco Group-Alexandria, Egypt (6 sites of API & DF), 32. Pharmastate Academy, 33. Aligned Automation, Qualigens Ltd., 34. QU Consulting-LLC, USA 35. Riva Pharma, Canada, 36. Sri Krishna Pharma, 37. Steril-Gene, 38. Syngene Ltd. 39. TagBox, 40. GMP Mfg UK,

## **Mentor, Board of Advisors-**

1. Govt of Maharashtra, Education Ministry- Technical Committee member for review of Pharmacy Course Curriculum and Education Policy & Recommendations (2025-2031), 2. WHO Geneva, 3. MGV Pharmacy College, Panchwati, Nashik, 4. UBM Conference, 5. BlueTech Conference, 6. EBM Conference, 7. CPhI Conference, 8. Pharma World CaseCon, 9. PharmaNow Magazine

# Services We Provide

## Role we play -

Enabling the process to facilitate the management at Board and Shop-Floor level to identify and help delivering strategic and transformational Quality leadership drive for imparting, *Culture of Pharmaceutical Quality*. Worked at global organisations across continents/ geographies to provide successful international growth initiative in Pharmaceutical, Bio-Pharmaceuticals, Herbal, Device, Healthcare, Cosmetics industry.

Mentoring, Training & handholding the site and corporate management to support and bring in the desired SOC – State of Control.

# Services We Provide

## Deliverables and achievements –

We have experience in on-site and off-site assessment of the GXP data. Provide effective compliance strategy and QIP (Quality Improvement Plan) for Quality Management. Services provided to various clientele- API- Intermediates, API/ DS, DF, Devices, IT- software, AI-ML.

Since, March 2020; we adopted seamlessly to go virtual & did CGMP activities due to the exigency caused due to Covid-19 Pandemic. During subsequent Lockdown we provided the remote review & CGMP assessment for developed Markets like USFDA, EU region – QMS Review, Batch Record Review and Release of the Sterile Finish Products. Proposed the WL Remediation strategy, Plan and CAP. Virtual CGMP Audit and due diligence. Virtual Training and mentoring and advisory for Global corporations.

# Services We Provide

## Deliverables and achievements –

1. Supported the **Remediation Program**, Warning Letter review, assessment, response and mentoring the site technical team.

*M/s. Killitch, M/s. Aragen Lifesciences., Baxter, Matoda Site, Shilpa Medicare- HYD, Brassica Pharma-Mumbai, Emcure- Pune DF & Kurkumh DS.*

2. Supported the **Greenfield/ Brownfield Projects** for Sterile and Non-Sterile DS & DF - Project for achieving WHO, PIC/s, ISO certification.

*M/s. Pharco Group, Alexandria, GMP UK. Eisai Pharma- Vizag. Aristo Pharma, Baroque Pharma, Kutch Gujarat,*

3. Supported and reviewed the **site preparedness** for USFDA, MHRA/ EMEA surveillance audit. SME training, CGMP Baseline Assessment, Training, Mentoring.

*M/s Koprana DS- Mahad, & DF- Khopoli. Steril-Gene- Pondicherry.*

# Services We Provide

## Deliverables and achievements –

4. Supported the **Training** on Data Integrity, CGMP, Culture of Pharmaceutical Quality.

*M/s Abbott India – DF Sites Baddi & Goa, and R&D Centre- Mumbai. Krishna Pharma., Hetero Drugs- Vizag, Bliss GVS Mumbai.*

5. **Due Diligence** of the DMF- DS and Intermediate Sites- M/s. Megafine- Dindori & Vapi. M/s. Innova Synth, Navi Mumbai., IQGenX- Pilot Facility Mumbai. Aristo Pharma-Mumbai, MetroChem API Pvt Ltd. HYD, Vizag

6. Supported the **NCE Program**, as Third Party Assessment, CGMP Audit- Anavex Inc. USA,

*M/s. Syngene Bangalore, DCTI/ Chiral Tech – HYD.*

## Deliverables and achievements –

7. **Dry Powder Inhaler-** 3<sup>rd</sup> Party assistance, PharmaMantra Associates- SME- Regulatory, Product development, Operations, QMS, Microbiology, Chem & Instrumentation, to manufacture for Canada/ US market, DPI, Ellipta (GSK) based on the USFDA & EMA Training and orientation of Riva Pharma Management Team, Montreal Canada.

- Device manufacturing and quality
- CMC, including DPI, MDI quality requirements
- Regulatory requirements for generic submissions as per US FDA and EMA guidelines, including clinical development ELLIPTA franchise (single, BREO, Trelegy) and RESPIMAT

## Deliverables and achievements –

8. **Soft Mist Inhaler (SMI)**- 3<sup>rd</sup> Party assistance, PharmaMantra Associates- SME- Operations, QMS, Microbiology, Chem & Instrumentation, to manufacture for US market, SMI- Respimat, Tiotropium 1.25mcg & 2.5 mcg.

- Product Development,
- Tech Transfer- Mfg and Analytical- Micro & Analytical,
- Vendor Qualification,
- Facility Qualification, Automation and IT controls,
- Training,
- APS- Media, Colour Media Protocol & Batch record preparation Implementation,
- Qualification- Steriliser, Robot, Filling machine/ Stoppering/ Canister Sealing/ Labelling m/c.
- Water & HVAC ORABS Smoke Study, WFI Runs, Training, IT and Quality Policy.

# Services We Provide

**Quality Learners**, group formed during Covid-19 Pandemic, in Oct'2020, having strong **490+ members**, who are - Mentors, Educators/ Teachers, Ex-colleagues, Referrals; having extensive rich experience in Pharmaceuticals, Biotechnology, Device, Pharma 4.0, Six Sigma. Members have worked in Academics, and in Industry as Head of R&D, Technology Transfer, Regulatory Agencies, Quality & Regulatory, Manufacturing, Engineering. Facilitation for a weekly talk, hosted by myself supported by a core committee.

A very interactive & motivating learning cum networking/ digital platform enabling various leaders/ SME - R&D, Quality, Production, Regulatory, FDA, WHO.

***Till date we have hosted/ conducted 282 Talk sessions/ webinars***

# Services We Provide




Greenfield Project, Facility & Equipment Gap assessment




Resource assessment and Remediation support



CGMP Gap Assessment



PDE Certification



Strategy & Consulting



Training

# Services We Provide

## Quality

- ❑ Strategy and advise - to formulate and implement a sustainable Quality System
- ❑ Gap Assessment Audits – GxP, Pre-approval inspection (PAI) readiness
- ❑ WL/ 483, Regulatory inspectional Review, Response writing (post inspection)
- ❑ Road Map, as corrective action plan (CAP), OAI/ VAI remediation & communication
- ❑ US Products Release, Review the Data, QMS assessment, Analytical & Batch Records
- ❑ Training & Certification - GxP compliance, Data Integrity, Investigation CAPA, Root Cause,
- ❑ Due diligence of DMF, ANDA – including R&D and Mfg and Testing sites/ facilities
- ❑ PDE & OEL Certification, as per EMEA Guidance


# Services We Provide

## Advisory

- ❑ Greenfield/ Brownfield- New Project, ideation and advice for Facility, Product, Contract Test Lab
- ❑ R & D, Scale-up, Manufacturing, Quality & Compliance Strategy
- ❑ Support review the prevailing- QMS. Review, Execution, Implementation
- ❑ Instill the Culture of Quality

## Consultancy


- ❑ Quality Management – R & D, Manufacturing Operations (API, DF, Devices), CRO, CMO
- ❑ Regulatory batches, data review, help in dossier submission and site readiness
- ❑ Resource Management for SOC (state of control)
- ❑ Remediation Program, GxP Compliance Strategies



# Purpose

To support organizations achieve their potential and proactively reach the desired milestones with a planned - **Strategy, Plan and Execution**.

This may be achieved by focusing on the **3Ps** –




This can be documented as commitment in **Quality Policy** signed by the Chairman or Managing Director. Giving clarity as Organisational - **VISION** and implemented as short term and long term Strategy as **MISSION**.

# Scope

To support organizations achieve their ***Vision, Mission and Strategic Milestones*** in end to end operations management. Integrating the New product development and operations to synchronize the ***Timely Launch*** and meet the ***Business Goals*** “Right First Time and Every Time”.




# Industry Relevance



This may be achieved by focusing on the above functions in the organisation – ***adequate project management and timely escalation of issue*** to Management can lead to harness the potential and proactively reach the desired milestones with a planned - Strategy, Plan and Execution.

# Industry Perspective



# Regulatory Strategy & Risk Assessment

## Lab to Launch expectations...

### Complex Drug Development Process


The drug development process is complex, consisting of many interrelated business activities and functional constituents participating in the “*Lab to Launch*” of any given product (Figure 1).




Figure 1 “*Lab to Launch*” Continuum

# Regulatory Strategy & Risk Assessment

Figure 1: Overview of a typical quality risk management process




# 5 step Mantra for Willing Transformation



**"If you are not willing to learn,  
no one can help you. If you are  
determined to learn, no one  
can stop you."**

ZIG ZIGLAR  
MATEUSZM.COM



# Lessons Learnt – Scaling manufacturing to meet commercial requirements

Understanding the functional requirements of each of the “swim lanes” and the inter-relationship across these constituents will define challenging areas to focus on for initiating this activity. A template of common drug development activities and constituents supporting this activity provides a starting point for many organizations beginning a business transformation process.



# Lessons Learnt – ALCOA

Although the **CGMPs** articulate a number of the expectations for data quality, the **GLP** regulations, , are the first FDA regulations which bring the ALCOA elements of data quality together in a comprehensive fashion.

For this reason, **the GLP requirements pertaining to data quality elements**, particularly **21 CFR 58.130(e)** which articulates virtually all the **elements of ALCOA**.

This acronym stands for :

1. **Attributable**,
2. **Legible**,
3. **Contemporaneous**,
4. **Original and**
5. **Accurate**.

The following are some general definitions, paraphrased from the Pharmaceutical Inspection Co-operation Scheme (PIC/S) (1), that can be used for understanding the elements of ALCOA and **ALCOA+**:

1. **Attributable:** The data generated or collected must be traceable back to the individual who generated the information.
2. **Legible:** The data recorded must be readable and permanent.
3. **Contemporaneous:** The results, measurements, etc. must be recorded at the time the work is performed.
4. **Original:** Original or source data are the record, report, notebook etc. where the data point was initially recorded.
5. **Accurate:** The data recorded must be complete, consistent, truthful, and representative of facts.

## Plus- CCEA

1. **Complete:** Information that is critical to recreating and understanding an event. This would include any repeat or reanalysis performed on a laboratory test sample.
2. **Consistent:** The data are presented, recorded, dated, or time-stamped in the expected and defined sequence.
3. **Enduring:** The data or information must be maintained, intact, and accessible throughout their defined retention period.
4. **Available:** The data or information must be able to be accessed at any time during the defined retention period.

# PharmaMantra™ –Modus Operandi

**US FDA and EU/ EDQM related activities performed in two ways  
Independently & Collaborative approach –**

***1. Independent approach –***

Managed by myself & invoiced and reported under "PharmaMantra™".

***2. Collaborative approach –***

Managed by other either by a consulting firm, as partner or consortium, supported by myself/ PharmaMantra™.

**A pool of experts is formed, members are based in India and developed countries, viz. US, EU –**

1. The SMEs in consortium are senior professionals having core experience - 20 to 50+ years. The age range is between 40 to 75 years.
2. All are having professional experience and exposure, regulated markets.
  - Pharmaceutical, Chemical Research and Manufacturing
  - Toxicological and Clinical
  - PAT, Pharma 4.0, Devices
  - CSV and GXP gap assessment and remediation
  - Sterile product manufacturing & Microbiology
  - Ex US FDA, CDER and Innovative technologies, Device, Biosimilars, Generic Drugs
3. Already established as consultants and advising in the developing economy and developed economy.

**A pool of experts is formed based in India and developed countries, viz. US, EU –**

Continued-

4. Individuals are experienced in evaluating GXP, CGMP systems of pharmaceutical manufacturers (viz. APIs, excipients, finished dosage form, analytical testing laboratory, medical device, and packaging).
5. The SMEs, managed small to large projects, conduct effective GMP, Due Diligence, Vendor Qualification audits and has good understanding of quality system, material system, facility & equipment system, production system, laboratory control system, packaging and labelling system (encompassing all the six systems of a pharmaceutical cGMP). Also expertise in evaluation of sterile manufacturing facility and various sterilization processes.

**A pool of experts is formed based in India and developed countries, viz. US, EU –**

Continued-


6. The team has experience in facing inspection by various health authorities (US FDA, EU, MHRA, EDQM, WHO, ANVISA etc.). Apart from facing number of facility inspections, the team has combined experience of facing 100 plus facility inspections from US FDA. Thus team is enriched with knowledge and experience of Regulatory agencies expectations. We have completed projects on quality management services for pre-inspection evaluation of QMS for EDQM and US FDA inspections of API and DF facilities.
7. Supported client in preparing response to 483 Observations issued at the end of US FDA Inspection of API facility. Gap assessment of QMS and remediation at API, Device & DF site. We had been associated with the client in preparing presentation and participated in face to face meeting with US FDA for GMP related Regulatory Meeting (API & Formulation facility).

**A pool of experts is formed based in India and developed countries, viz. US, EU –**

Continued-


8. Dossier outsourcing, Product and Method Development, India, ROW and US and EU markets.
9. Supported in development, validation and execution of the software and hardware for facility management. Facility CSV and equipment qualification and life cycle management, as per 21CFR, GAMP.
10. Assessment and certification of the PDE, Permitted Daily Exposure for API and Dosage Forms.
11. Training on the GXP Topics, emphasis on the learning and un-learning by willing transformation. Workshops including Presentation, Case Studies, Movies, for Audio and Video impact for enabling effective learning.

# Summary –



**2 sides of a coin may be different- does not lose value, Opportunity & Challenges are always there...**

# Learning.....Challenges – Documents.....Records...



# Learning.....Challenges – Unlearning.....No Repeats....mistakes

## New Product development

- Identification of Candidate – Business Case
- Develop – Dosage, Prototype Process, Method (innovator)
- Bio-batches, Clinical, BA/ BE studies
- Investigations of Failure - Learning


## Technology Transfer & scale-up

- Scale-up of Batch Process, Method of Analysis, Specifications,
- Validation, Reproducibility, Process Capability
- Investigations of Failure – Process Optimisation

## Post Approval & Commercialization

- Change Control - Batch Process, Method of Analysis, Specifications,
- Investigations of Failure - Trend
- CPV, Monitoring the Process Capability
- PLM (lifecycle management)

# Bhagavad Gita:



## Willing Transformation

**Arjuna** was advised by **Krishna** in battlefield.

1. Listened
2. Thought
3. Acted

**Sanjaya**, who was viewing, listening and telecasting the happenings to **Dhritrashtra**.

**Dhritrashtra** was listening to the blow by blow account.

The three individuals were listening....only one heard and then was willing to transform. Arjuna's **self was involved** in the process of transformation and then he led the Pandavas...

**Arjunas, transformation lead to the Pandavas victory in 18 days Mahabharata.**



यदृच्छालाभसन्तुष्टो द्वन्दवातीतो विमत्सरः ।  
समः सिद्धावसिद्धौ च कृत्वापि न निबध्यते ॥ 22॥

*yadṛichchhā-lābha-santuṣṭo dvandvātīto vimatsarah  
samaḥ siddhāvasiddhau cha kṛtvāpi na nibadhyate*

yadṛichchhā—which comes of its own accord; lābha—gain; santuṣṭah—contented; dvandva—duality; atītah—surpassed; vimatsarah—free from envy; samaḥ—equipoised; siddhau—in success; asiddhau—failure; cha—and; kṛtvā—performing; api—even; na—never; nibadhyate—is bound

**BG 4.22:** Content with whatever gain comes of its own accord, and free from envy, they are beyond the dualities of life. Being equipoised in success and failure, they are not bound by their actions, even while performing all kinds of activities.

*While living in this world, nobody can hope to neutralize the dualities to have only positive experiences.*


*Then how can we successfully deal with the dualities that come our way in life? The solution is to take these dualities in stride, by learning to rise above them in equipoise in all situations.*

*This happens when we develop detachment to the fruits of our actions, concerning ourselves merely with doing our duty in life without yearning for the results.*

## 5 step Mantra for Willing Transformation

1. **Acquiring Knowledge**
2. Regular **Training** and develop a new **Habit**; eliminate bad habits
3. **Learning** & be receptive – environment, changes; **Unlearning**
4. In doubt **seek advice** - Role Model/ Guru; **correct course/** action plan
5. **Self actualisation** – **Implementation** of Knowledge; **Skill - Mastery**
6. *Transformed, individual - Organisation*

I refuse to go back to  
the old me. I'm becoming  
a better person using  
my past experiences as  
lessons.



# Our Website: Home

DEVELOPING INNOVATIVE STRATEGIES

# RIGHT FIRST TIME AND EVERY TIME

Supporting higher management to identify and delivering strategic and transformational Quality leadership drive for imparting Culture of Pharmaceutical Quality to provide successful international growth initiative in Pharmaceutical, Healthcare, Cosmetics.



# Our Website: Services

## Role of Founder of PharmaMantra™- Since Aug' 2017 –

Enabling the process to facilitate the management at Board and Shop-Floor level to identify and help delivering strategic and transformational Quality leadership drive for imparting, *Culture of Pharmaceutical Quality*. Worked at global organisations across continents/ geographies to provide successful international growth initiative in Pharmaceutical, Bio-Pharmaceuticals, Herbal, Device, Healthcare, Cosmetics industry.

Mentoring, Training & handholding the site and corporate management to support and bring in the desired SOC – State of Control.

## Deliverables and Achievements –

We have experience in on-site and off-site assessment of the GXP data. Provide effective compliance strategy and QIP (Quality Improvement Plan) for Quality Management. Services provided to various clientele- API- Intermediates, API/ DS, DF, Devices, IT- software, AI-ML. Since, March 2020; we adopted seamlessly to go virtual & did CGMP activities due to the exigency caused due to Covid-19 Pandemic. During subsequent Lockdown we provided the remote review & CGMP assessment for developed Markets like USFDA, EU region – QMS Review, Batch Record Review and Release of the Sterile Finish Products. Proposed the WL Remediation strategy, Plan and CAP. Virtual CGMP Audit and due diligence. Virtual Training and mentoring and advisory for Global corporations.



<https://www.pharmantra.expert/services/>

# Our Website: About us



Udaykumar K. Rakibe, M.Pharm. Ph.D. MBA

## ABOUT US

Udaykumar is a quality professional with a dynamic career steering organization through complex Quality & Regulatory challenges, transitions, building an empowered and talented workforce in the cross-cultural environment within highly competitive products and regulatory environment.

In Year 2006, as Director – Quality Assurance, he was mandated and given the task to execute and spearhead the proactive remediation at Ranbaxy Lab. Ltd. Subsequently since Daichii Sankyo takeover, he was made Head, India and Asia Quality Operations and overseeing the state of control. In late 2011 he was recruited by Intas Pharma Ltd. to create a self-sustaining quality management system and enhance inspection readiness. Further, in 2013 he was hand-picked & recruited by Wockhardt Ltd., as Senior Vice President – Quality, to turn around the Quality Management, lead and manage the remediation of Quality initiatives. In 2021 Morison Sri Lanka, brought him on board as Chief Quality Officer-CQO, to achieve and realize the vision of the MD & Chairman to have a State-of-the Art facility at Homagama, Colombo. He has represented the Organisation as Quality Head and prepared, presented and attended the regulatory meetings with IAG/ MHRA/ IMB/ USFDA at London and Washington respectively. As a Quality professional, has performed 400+ Audits and faced 500+ regulatory audits.

He began his career in Quality function as an Executive In-process QA and then moved to different levels and organization spanning 27 plus years of hands-on and hard-core experience in the pharmaceutical regulatory environment. He has gained the domain experience in Quality & Operations, specifically focusing and leading the Quality & Regulatory remediation in last 12 years (2006-2017). He has worked for a decade in



# Our Website: Contact

## CONTACT US

# Need Assistance? Reach Out

Have any query? Get in touch with us now!



**Company Phone**  
(+91) 7756848484



**Company Mail**  
Pharmantra.expert@gmail.com



**Address**  
803, Orchid, Dream Flower, Opposite Croma/ Vijay Mamta Cinemas,  
Nashik Pune Highway, Bodhale Naagar, Nashik, Maharashtra- 422011

Name

Email

Message

Write your message here...

Let's Get Started

